**Document No. 00**

**Invitation to offer for NHS National Pharmaceuticals Transition 2020\_2**

**Offer reference number: CM/PHG/19/5618**

**Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)**

**Potential periods of call-offs under the framework agreement:**

**Transition Products: LSNE 01/12/2020 to 30/09/2021 (10 months)**

**NWLN 01/12/2020 to 31/01/2022 (14 months)**

**CESW 01/12/2020 to 30/06/2022 (19 months)**

**Hospital Only Products: All Regions 01/12/2020 to 31/01/2022 (14 months)**

This procurement is for a variety of drugs, we would like to bring the following information, pertinent to the specific drugs within this procurement to your attention.

This is procurement for generic drugs:

|  |
| --- |
| OXYCODONE/NALOXONE MR TABLET 10MG/5MG |
| OXYCODONE/NALOXONE MR TABLET 5MG/2.5MG |
| OXYCODONE/NALOXONE MR TABLET 20MG/10MG |
| OXYCODONE/NALOXONE MR TABLET 40MG/20MG |

For all uses except the use “ *in the treatment of patients with restless leg syndrome (RLS).”*

The Authority understands that fewer than 5% of oxycodone / naloxone prescriptions are for the treatment of patients with restless leg syndrome.

Please note that the full list of products included in the procurement are listed within Document No. 05a(i) and 5a(iii) of this Invitation to Offer pack, including separate descriptions for any products that are not limited in use as above.